医学
皮疹
慢性粒细胞白血病
不利影响
内科学
髓系白血病
呕吐
腹泻
胃肠病学
白血病
酪氨酸激酶抑制剂
毒性
恶心
外科
癌症
作者
Lei Jiang,Mingzhen Yang
出处
期刊:PubMed
日期:2023-04-15
卷期号:78 (1): 13-16
摘要
The present study aimed to investigate the efficacy and safety of flumatinib in patients newly diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). A retrospective study was conducted using five patients newly diagnosed with CML-CP who received flumatinib (600 mg/day). Results of the present study demonstrated that all five patients with CML-CP that were treated with flumatinib achieved the optimal molecular response within three months. In addition, two patients experienced major molecular response (MMR), and one patient acquired undetectable molecular residual disease, which was maintained for more than one year. Moreover, one patient exhibited grade 3 hematological toxicity, two patients exhibited transient diarrhea, one patient exhibited vomiting and one patient exhibited a rash with pruritus. No second-generation tyrosine kinase inhibitor-specific adverse cardiovascular events occurred in any patients. In conclusion, flumatinib exhibits high efficacy and high early molecular response rate in patients newly diagnosed with CML-CP. The majority of patients obtained MMR within three months, and the adverse reactions experienced were mild and tolerable.
科研通智能强力驱动
Strongly Powered by AbleSci AI